1. A Real-world Study on Prescription Pattern of Fosfomycin in Critical Care Patients.
- Author
-
Zirpe, Kapil G., Mehta, Yatin, Pandit, Rahul, Pande, Rajesh, Deshmukh, Abhijit M., Patil, Saiprasad, Bhagat, Sagar, and Barkate, Hanmant
- Subjects
- *
EVALUATION of medical care , *INTENSIVE care units , *CRITICALLY ill , *PATIENTS , *RETROSPECTIVE studies , *INFECTION , *SEPSIS , *DRUG prescribing , *CRITICAL care medicine , *PHYSICIAN practice patterns , *HYPOKALEMIA , *ANTIBIOTICS , *PATIENT safety - Abstract
Background: This study presents a real-world scenario for prescription pattern, efficacy, and safety data on the current clinical use of intravenous fosfomycin in critically ill patients in Indian settings. Patients and methods: This was a retrospective cohort study conducted for a period of 10 months among critically ill patients admitted to hospital's critical care unit. The primary objective of the study was to analyze the prescription pattern of intravenous fosfomycin, and the secondary objective was to evaluate the safety profile and patient outcomes. Results: A total of 309 patients were enrolled, and they were diagnosed with bacteremia (45.3%), pneumonia (15.85%), septic shock (14.24%), and urinary tract infections (UTI) (13.91%). The average dose of fosfomycin given was 11.7 ± 4.06 gm/day. The average duration of the therapy was 4.85 ± 3.59 days with a median duration of 4 days. Fosfomycin was given at 8 hourly dosing frequency to maximum (45.6%) cases. Hypokalemia was the most observed adverse event. The overall survival was seen in 55% of patients. Conclusion: Our data suggest that UTI, infection caused by Escherichia coli, and a daily dose of >12 g were associated with better clinical outcomes. The overall survival of critically ill patients receiving fosfomycin was 55%. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF